Visakorpi T - Search Results

1

The Potential of MicroRNAs as Prostate Cancer Biomarkers.

Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA. Fabris L, et al. Among authors: visakorpi t. Eur Urol. 2016 Aug;70(2):312-22. doi: 10.1016/j.eururo.2015.12.054. Epub 2016 Jan 22. Eur Urol. 2016. PMID: 26806656 Free PMC article. Review.

2

New prognostic factors in prostatic carcinoma.

Visakorpi T, Kallioniemi OP, Koivula T, Isola J. Visakorpi T, et al. Eur Urol. 1993;24(4):438-49. doi: 10.1159/000474347. Eur Urol. 1993. PMID: 8287885 Review. No abstract available.

3

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.

Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T. Palmberg C, et al. Among authors: visakorpi t. Eur Urol. 1997;31(2):216-9. doi: 10.1159/000474453. Eur Urol. 1997. PMID: 9076469

4

Molecular biology of progression of prostate cancer.

Nupponen N, Visakorpi T. Nupponen N, et al. Among authors: visakorpi t. Eur Urol. 1999;35(5-6):351-4. doi: 10.1159/000019907. Eur Urol. 1999. PMID: 10325488 Review.

5

PSA decline is an independent prognostic marker in hormonally treated prostate cancer.

Palmberg C, Koivisto P, Visakorpi T, Tammela TL. Palmberg C, et al. Among authors: visakorpi t. Eur Urol. 1999 Sep;36(3):191-6. doi: 10.1159/000067996. Eur Urol. 1999. PMID: 10450001

6

Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Palmberg C, et al. Among authors: visakorpi t. J Urol. 2000 Dec;164(6):1992-5. J Urol. 2000. PMID: 11061898

7

Molecular genetics of prostate cancer.

Elo JP, Visakorpi T. Elo JP, et al. Among authors: visakorpi t. Ann Med. 2001 Mar;33(2):130-41. doi: 10.3109/07853890109002068. Ann Med. 2001. PMID: 11327116 Free article. Review.

8

Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.

Isola J, Auvinen A, Poutiainen M, Kakkola L, Järvinen TA, Määttänen L, Stenman UH, Tammela T, Hakama M, Visakorpi T. Isola J, et al. Among authors: visakorpi t. J Urol. 2001 May;165(5):1569-74. J Urol. 2001. PMID: 11342919 Clinical Trial.

9

The molecular genetics of prostate cancer.

Visakorpi T. Visakorpi T. Urology. 2003 Nov;62(5 Suppl 1):3-10. doi: 10.1016/s0090-4295(03)00776-3. Urology. 2003. PMID: 14607212 Review.

10

Molecular mechanisms of prostate cancer.

Porkka KP, Visakorpi T. Porkka KP, et al. Among authors: visakorpi t. Eur Urol. 2004 Jun;45(6):683-91. doi: 10.1016/j.eururo.2004.01.012. Eur Urol. 2004. PMID: 15149739 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

297 results

Search Page

Filters